Ruxolitinib Phosphate

Catalog No.S5243 Synonyms: INCB018424, INC424

Ruxolitinib Phosphate Chemical Structure

Molecular Weight(MW): 404.36

Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities.

Size Price Stock Quantity  
USD 107 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective JAK Inhibitors

Biological Activity

Description Ruxolitinib Phosphate is the phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities.

Protocol

References

Solubility (25°C)

In vitro DMSO 80 mg/mL (197.84 mM)
Water 29 mg/mL (71.71 mM)
Ethanol 8 mg/mL (19.78 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.36
Formula

C17H18N6.H3O4P

CAS No. 1092939-17-7
Storage powder
in solvent
Synonyms INCB018424, INC424

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01787552 Completed Primary Myelofibrosis|Thrombocythemia Essential|Thrombocytosis|Myeloproliferative Disorders|Bone Marrow Diseases|Hematologic Diseases|Blood Coagulation Disorders|Blood Platelet Disorders|Hemorrhagic Disorders Novartis Pharmaceuticals|Novartis May 8 2013 Phase 1|Phase 2
NCT03011892 Completed Atopic Dermatitis Incyte Corporation December 2016 Phase 2
NCT02553330 Terminated Alopecia Areata (AA) Incyte Corporation October 2015 Phase 2
NCT01644110 Recruiting Primary Myelofibrosis|Secondary Myelofibrosis|PMF|SMF|Post-PV MF|Post-ET MF University of Ulm August 2013 Phase 1|Phase 2
NCT01558739 Completed Primary Myelofibrosis (PMF)|Post Polycythaemia Myelofibrosis (PPV MF)|Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Novartis Pharmaceuticals|Novartis May 2012 Phase 4
NCT01348490 Active not recruiting MPN (Myeloproliferative Neoplasms) Incyte Corporation June 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

JAK Signaling Pathway Map

Related JAK Products

Tags: buy Ruxolitinib Phosphate | Ruxolitinib Phosphate supplier | purchase Ruxolitinib Phosphate | Ruxolitinib Phosphate cost | Ruxolitinib Phosphate manufacturer | order Ruxolitinib Phosphate | Ruxolitinib Phosphate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID